Urine markers in monitoring for prostate cancer

被引：67

作者：

Jamaspishvili, T. ^{[1
]}

Kral, M. ^{[2
]}

Khomeriki, I. ^{[2
]}

Student, V. ^{[2
]}

Kolar, Z. ^{[1
]}

Bouchal, J. ^{[1
]}

机构：

[1] Palacky Univ, Lab Mol Pathol, Fac Med & Dent, CZ-77515 Olomouc, Czech Republic

[2] Univ Hosp, Dept Urol, Olomouc, Czech Republic

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2010年 / 13卷 / 01期

关键词：

urine marker; multiplex analysis; TMPRSS2-ERG GENE FUSION; COENZYME-A RACEMASE; ENDOTHELIAL GROWTH-FACTOR; DNA-BASED DETECTION; TELOMERASE ACTIVITY; BLADDER-CANCER; ETS FAMILY; NONINVASIVE DETECTION; TRANSCRIPTION FACTORS; MOLECULAR DIAGNOSIS;

D O I：

10.1038/pcan.2009.31

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci. Almost all urine-detectable prostate-specific markers have been recently reviewed. For this reason, we focus here on only a few promising markers which have been independently evaluated (in particular PCA3, fusion genes, TERT, AMACR, GSTP1, MMP9 and VEGF) and very recent ones (ANXA3 and sarcosine). The emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. A combination of multiple urine biomarkers may be valuable in the case of men with persistently elevated serum prostate-specific antigen and a history of negative biopsies. The emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment. Prostate Cancer and Prostatic Diseases (2010) 13, 12-19; doi:10.1038/pcan.2009.31; published online 4 August 2009

引用

页码：12 / 19

页数：8

共 108 条

[1]

Afar DEH, 2001, CANCER RES, V61, P1686

[2]

Overexpression of Ets-1 proto-oncogene in latent and clinical prostatic carcinomas [J].

Alipov, G ;

Nakayama, T ;

Ito, M ;

Kawai, K ;

Naito, S ;

Nakashima, M ;

Niino, D ;

Sekine, I .

HISTOPATHOLOGY, 2005, 46 (02) :202-208

[3]

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Mills, I. G. ;

Fisher, G. ;

Flohr, P. ;

Reid, A. ;

Edwards, S. ;

Kovacs, G. ;

Berney, D. ;

Foster, C. ;

Massie, C. E. ;

Fletcher, A. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

BRITISH JOURNAL OF CANCER, 2008, 99 (02) :314-320

[4]

TMPRSS2-ERG fusion heterogeneity in Multifocal prostate cancer: Clinical and biologic implications [J].

Barry, Marc ;

Perner, Sven ;

Demichelis, Francesca ;

Rubin, Mark A. .

UROLOGY, 2007, 70 (04) :630-633

[5]

Bok RA, 2001, CANCER RES, V61, P2533

[6]

Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity [J].

Botchkina, GI ;

Kim, RH ;

Botchkina, IL ;

Kirshenbaum, A ;

Frischer, Z ;

Adler, HL .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3243-3249

[7]

Bussemakers MJG, 1999, CANCER RES, V59, P5975

[8]

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions [J].

Cerveira, Nuno ;

Ribeiro, Franclim R. ;

Peixoto, Ana ;

Costa, Vera ;

Henrique, Rui ;

Jeronimo, Carmen ;

Teixeira, Manuel R. .

NEOPLASIA, 2006, 8 (10) :826-832

[9]

Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy:: A longitudinal study of protein kinetics throughout tumor progression and therapy [J].

Chan, LW ;

Moses, MA ;

Goley, E ;

Sproull, M ;

Muanza, T ;

Coleman, CN ;

Figg, WD ;

Albert, PS ;

Ménard, C ;

Camphausen, K .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :499-506

[10]

Role of the TMPRSS2-ERG gene fusion in prostate cancer [J].

Chinnaiyan, Arul M. .

NEOPLASIA, 2008, 10 (02) :177-U23

← 1 2 3 4 5 6 7 8 9 10 →